A research agenda for curing chronic hepatitis B virus infection

Harvey Alter, Timothy Block, Nathaniel Brown, Alan Brownstein, Carol Brosgart, Kyong‐Mi Chang, Pei‐Jer Chen, Francis V. Chisari, Chari Cohen, Hashem El‐Serag, Jordan Feld, Robert Gish, Jeffrey Glenn, Tim Greten, Haitao Guo, Ju‐Tao Guo, Yujin Hoshida, Jianming Hu, Kris V. Kowdley, Wenhui Li, Jake Liang, Stephan Locarnini, Anna S. Lok, William Mason, Brian McMahon, Anand Mehta, Robert Perrillo, Peter Revill, Charles M. Rice, JoAnn Rinaudo, Raymond Schinazi, Christoph Seeger, Kirty Shetty, John Tavis, Fabien Zoulim – 6 September 2017

Chronic hepatitis C virus (HCV) increases the risk of chronic kidney disease (CKD) while effective HCV treatment decreases the incidence of CKD

Haesuk Park, Chao Chen, Wei Wang, Linda Henry, Robert L. Cook, David R. Nelson – 5 September 2017 – We assessed the risk of chronic kidney disease (CKD) in chronic hepatitis C virus (HCV)‐infected patients and the incidence reduction of CKD after receipt of HCV treatment. We also evaluated the risk of membranoproliferative glomerulonephritis (MPGN) and cryoglobulinemia in chronic HCV patients. A retrospective cohort analysis of the Truven Health MarketScan Database (2008‐2015) in the United States was conducted.

Gene‐disease associations identify a connectome with shared molecular pathways in human cholangiopathies

Zhenhua Luo, Anil G. Jegga, Jorge A. Bezerra – 2 September 2017 – Cholangiopathies are a diverse group of progressive diseases whose primary cell targets are cholangiocytes. To identify shared pathogenesis and molecular connectivity among the three main human cholangiopathies (biliary atresia [BA], primary biliary cholangitis [PBC], and primary sclerosing cholangitis [PSC]), we built a comprehensive platform of published data on gene variants, gene expression, and functional studies and applied network‐based analytics in the search for shared molecular circuits.

Subscribe to